Gastric cancer is not a top‐10 malignancy in the United States but represents one of the
most common causes of cancer death worldwide. Biological differences between tumors …

Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Gastric cancer remains a considerable health burden throughout the world. The Cancer
Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with …

The overall 5-year survival of gastric cancer (GC) has change only little in the last decades
and it remains the fifth leading cause of cancer-related death worldwide. However, in the …

The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in
recent years. We have reviewed the recent data of clinical trial incorporating targeted …

Gastric cancer is a cause of significant morbidity and cancer-related mortality worldwide.
Despite recent advances in targeted therapy and understanding of the biology and …

Opinion statement For patients with advanced gastric cancer, traditional double or triplet
cytotoxic chemotherapy regimens result in a median survival of 9–11 months. As …

Gastric cancer currently ranks fourth in cancer-related mortality worldwide. In the western
world, it is most often diagnosed at an advanced stage, after becoming metastatic at distant …

Adequately powered, randomized phase III trials are necessary to define the clinical role of
targeted therapies in advanced gastric cancer. Biomarker studies to correlate with treatment …

Despite a decrease in incidence over past decades, gastric cancer remains a major global
health problem. In the more recent period, survival has shown only minor improvement …